Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

Neuralstem's Cell Therapy Is Working, And This Is Just The Beginning

Back in February 2014, we wrote an article for Seeking-Alpha reviewing the recently published Phase 1 data on Neuralstem's (NYSEMKT:CUR) NSI-566 for the treatment of Amyotrophic Lateral Sclerosis ("ALS"). This article is now exclusive to PRO subscribers, but we can point investors to the full peer-reviewed paper published in the Annals of Neurology (Feldman et al, 2014) for a comprehensive review of the Phase 1 study. Below we summarize some of the conclusions from that paper, and then point to significant anecdotal evidence that the current Phase 2 study is not only proceeding well, but succeeding in its primary goal of demonstrating safety and efficacy of NSI-566 for the treatment of ALS.

…Quick Review of ALS,

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details